Neuromuscular Complexity During Gait is not Responsive to Medication in Persons with Parkinson’s Disease
- 458 Downloads
The purpose of this study was to investigate the effects of dopaminergic therapy on neuromuscular complexity during gait and on the relationship between neuromuscular complexity and gait speed in persons with Parkinson’s disease (PD). Nine persons with PD walked at self-selected speed for 5 min after having withdrawn from dopaminergic medication for at least 12 h and while optimally-medicated. Electromyographic recordings were taken from eight leg muscles bilaterally. Non-negative matrix factorization was applied to reduce the dimensionality of the electromyographic signals into motor modules. We assessed neuromuscular complexity by investigating the number, structure, and timing of the modules. We also investigated the influence of dopaminergic medication on the relationships between neuromuscular complexity and gait speed. Though gait speed increased significantly after medication intake, medication did not affect neuromuscular complexity. Neuromuscular complexity was significantly associated with gait speed only while the participants were medicated. Thus, the supraspinal structures that govern neuromuscular complexity during gait do not appear to be solely dopaminergically-influenced in PD. The lack of dopaminergic influence on neuromuscular complexity may explain why persons with PD exhibit gait slowness even while medicated, and an intervention that restores neuromuscular complexity may result in gait speed improvement in PD.
KeywordsMotor modules Muscle Lower extremity Electromyography Dopamine Levodopa Non-negative matrix factorization Decomposition
This work was supported in part by NIH grants 1R21AG033284-01A2 and UF National Parkinson’s Foundation Center of Excellence. We would also like to thank Dr. Umer Akbar and Dr. Nawaz Hack for their assistance in scoring the UPDRS videos.
Conflict of interest
The authors declare that there are no relevant conflicts of interest.
- 4.Birkmayer, W., and O. Hornykiewicz. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien KlinWochenschr. 73:787–788, 1961.Google Scholar
- 16.Hass, C. J., M. D. Bishop, M. Moskovich, E. L. Stegemöller, J. W. Skinner, I. A. Malaty, A. Wagle Shukla, K. N. McFarland, and M. S. Okun. Defining the clinically meaningful difference in gait speed in Parkinson’s disease. J. Neurol. Phys. Ther. (2014, accepted).Google Scholar
- 20.Karachi, C., D. Grabli, F. A. Bernard, D. Tandé, N. Wattiez, H. Belaid, E. Bardinet, A. Prigent, H. P. Nothacker, S. Hunot, A. Hartmann, S. Lehéricy, E. C. Hirsch, and C. François. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Invest. 120:2745–2754, 2010.PubMedCentralPubMedCrossRefGoogle Scholar
- 26.Pierantozzi, M., M. G. Palmieri, S. Galati, P. Stanzione, A. Peppe, D. Tropepi, L. Brusa, A. Pisani, V. Moschella, M. G. Marciani, P. Mazzone, and A. Stefani. Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson’s disease patients. J. Neural Transm. 115:731–735, 2008.PubMedCrossRefGoogle Scholar
- 30.Rolland, A. S., D. Tandé, M. T. Herrero, M. R. Luquin, M. Vazquez-Claverie, C. Karachi, E. C. Hirsch, and C. François. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. J. Neurochem. 110:1321–1329, 2009.PubMedCrossRefGoogle Scholar